Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Foundation Medicine Extends and Expands Collaboration with Novartis

Published: Wednesday, January 08, 2014
Last Updated: Tuesday, January 07, 2014
Bookmark and Share
Collaboration will now extend through at least September 2016.

Foundation Medicine has announced that it has extended and expanded its ongoing collaboration with Novartis to provide molecular information and comprehensive genomic profiling analysis in support of many of Novartis' clinical oncology programs.

As the result of Foundation Medicine and Novartis' pilot program established in January 2011 and an expanded three-year agreement in June 2012, Foundation Medicine's comprehensive genomic profiling has generated clinically relevant data and is now regularly used in many of Novartis' oncology clinical trials.

This new agreement, which the companies agreed to extend and expand prior to the end of the existing term, includes committed capacity for Foundation Medicine to provide genomic profiling of patient samples from Novartis clinical trials, as well as access to Foundation Medicine's molecular information and analysis services.

The new three-year agreement also gives Novartis the option to extend the term for an additional two-year period. Financial terms are not being disclosed.

"We are deeply committed to our relationship with Novartis and pleased with the continued growth of our collaboration," said Michael J. Pellini, M.D., president and CEO, Foundation Medicine.

Pellini continued, "In addition to providing comprehensive genomic profiling for patients in Novartis clinical trials, this expanded agreement will allow Novartis to take advantage of our unique and growing database of molecular information to support the evaluation and development of Novartis' oncology drug candidates, biological targets and clinical trials."

Foundation Medicine uses comprehensive, clinical grade next-generation sequencing to assess routine cancer specimens for all genes that are currently known to be somatically altered and unambiguous drivers of oncogenesis in solid tumors and hematologic malignancies, as well as many sarcomas and pediatric cancers.

Novartis uses these capabilities to support its targeted therapy clinical development efforts by helping to align the genomic profile of individual patient's cancer with clinical trial enrollment criteria and clinical outcome analysis.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Foundation Medicine, IMS Health Collaborate
IMS Health will combine its Real-World Evidence platform with Foundation Medicine's FoundationCore knowledge base, enabling clients to interpret real-world oncology outcomes, the firms said today.
Tuesday, June 23, 2015
Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration
Collaboration to address needs of biopharmaceutical companies conducting clinical R&D in China.
Friday, October 31, 2014
Foundation Medicine and Memorial Sloan-Kettering Cancer Center Announce Partnership
Partners will co-develop a genomic test to help guide treatment decisions for patients diagnosed with leukemia, lymphoma or myeloma.
Friday, May 03, 2013
Foundation Medicine and AstraZeneca Announce Genomic Profiling Collaboration
Collaboration seeks to enhance clinical trial design by identifying genomic predictors of response to targeted cancer therapies.
Monday, November 12, 2012
Foundation Medicine Announces $42.5 Million Series B Financing
Syndicate includes leading public and strategic investors; proceeds will expand commercial operations and accelerate adoption of FoundationOne™.
Monday, October 01, 2012
Foundation Medicine Enters Extensive Collaboration with Novartis
Pilot agreement extended to a broad financial commitment over three years.
Monday, June 11, 2012
Foundation Medicine’s Next-Generation Sequencing Data to be Presented at 103rd AACR Annual Meeting 2012
Genomic profile demonstrates high concordance with existing commercial assays and identifies broader range of actionable alterations.
Wednesday, March 28, 2012
Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer
Findings highlight clinical application of next-generation sequencing to suggest targeted therapeutic options for patients.
Tuesday, February 14, 2012
Foundation Medicine Receives CLIA Certification for Its Genomic Sequencing Laboratory
This certification follows receipt of a Massachusetts State license and allows the company to accept clinical samples from most U.S. states.
Friday, February 03, 2012
Foundation Medicine Announces Collaboration with Sanofi
Fifth partnership will help translate cancer genomic science to clinical results. Foundation Medicine will use their genomic sequencing and analytic capabilities to identify genetic biomarkers and potential companion diagnostics for select Sanofi oncology drug candidates.
Friday, January 13, 2012
Foundation Medicine Appoints Molecular Diagnostics Industry Leader Maureen T. Cronin, Ph.D., as Senior Vice President of Research and Product Development
Foundation Medicine, Inc., a personalized cancer medicine company that aims to bring comprehensive cancer genome analysis to routine clinical care, have announced the appointment of Maureen T. Cronin, Ph.D., to the newly created position of senior vice president, research and product development.
Tuesday, November 16, 2010
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos